People · Operator
Named in public records as an officer, director or promoter · active 2015–2022 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| RayzeBio, Inc. | — | Biotechnology | Series D+ | $396.4M | $3.4B | 2020 |
| Metacrine, Inc. | — | Pharmaceuticals | Series C | $124.8M | $2.3B | 2015 |
Ken Song at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ken Song on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kristina Burow | 1 | 16 |
| Amir Nashat | 1 | 14 |
| Jerel Davis | 1 | 13 |
| Aaron Royston | 1 | 7 |
| Maha Katabi | 1 | 6 |
| Carol Gallagher | 1 | 6 |
| Aaron Kantoff | 1 | 6 |
| Robert Adelman | 1 | 5 |
| Neil McDonnell | 1 | 4 |
| Mary Tagliaferri | 1 | 3 |
| Kenneth Song | 1 | 2 |
| Ronald Evans | 1 | 2 |
| Richard Heyman | 1 | 2 |
| Trisha Millican | 1 | 2 |
| Arvind Kush | 1 | 2 |
| Deborah Charych | 1 | 2 |
| Angie You | 1 | 2 |
| Alex Rosen | 1 | 2 |
| Yi Larson | 1 | 1 |
| Jackie Hernandez | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.